IL165790A - Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof - Google Patents
Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereofInfo
- Publication number
- IL165790A IL165790A IL165790A IL16579004A IL165790A IL 165790 A IL165790 A IL 165790A IL 165790 A IL165790 A IL 165790A IL 16579004 A IL16579004 A IL 16579004A IL 165790 A IL165790 A IL 165790A
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- phenyl
- crc6
- agonists
- radical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
The invention relates to compounds of formula (I), in which R1, R2, R3, R4, R5 and R6 are defined as cited, in addition to their physiologically compatible salts. The compounds are suitable for use e.g. as hypolipidaemics.
Claims (18)
1. A compound of the formula I in which R1 , R2, R3, R4, R5, R6 independently of one another are (C0-C3o)- alkylene-(LAG)n, where n may be 1 - 5 and where one or more carbon atoms of the alkylene radical may be replaced by -S(0)n-, where n = 0 - 2, -0-, -(C=Oh -(C=S)-, -CH=CH-, -C≡C-, -N((C C6)-alkyl)-, -N(phenyl)- , -N((CrC6)-alkyl-phenyl)- , -N(CO-(CH2)i-io-COOH)- or -NH-; H, F, CI, Br, I, CF3l Q2, N3, CN, COOH, COOid-Ce alkyl, CONH2, CONH(C C6)-alkyl, CON[(C C6)-alkyl]2, (C C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, 0-(CrC6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; PO3H2, SO3H, S02-NH2( S02NH(C C6)-alkyl, S02N[(C C6)-alkyl]2 , S-(C C6)-alkyl, S-(CH2)n-phenyl, SO-(CrC6)-alkyl, SO- (CH2)n-phenyl, S02-(CrC6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 165790/2 37 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3, N02, CN, OCF3, 0-(CrC6)-alkyl, (d-Ce^alkyl, NH2; NH2, NH-(C C6)-alkyl, N((C C6)-alkyl)2, NH(C C7)-acyl, phenyl, O- (CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be mono- to trisubstituted by F, CI, Br, I, OH, CF3, N02, CN, OCF3, 0-(C C6)-alkyl, (Ci-CB)-alkyl, NH2, NH(C C6)-alkyl, N((CrC6)-alkyl)2l S02-CH3, COOH, COO-(CrC6)-alkyl, CONH2; (LAG)n is a mono-, di- or tricyclic trialkylammonium radical, a mono-, di- or tricyclic trialkylammoniumalkyl radical, -(CH2)0-io-C(=NH)(NH2), -(CH2)0. 1D-C(=NH)(NHOH) or -NR7-C(=NR8)(NR9R10); R7, R8, R9 and R10 independently of one another are H, (C C6)-alkyl, (C C6)- alkyl-phenyl, phenyl, (C3-Ce)-cycloalkyl); is 1 , 2, 3, 4, 5; where in each case at least one of the radicals R1 to R6 must have the meaning (Co-C3o)-alkylene-(LAG)n, where n = 1 - 5 and where one or more carbon atoms of the alkylene radical may be replaced by -S(0)n-, where n = 0 - 2, -0-, -(C=0)-, -( C=S)-, -CH=CH-, -C≡C-, -N((C C6)-alkyl)-, -N(phenyl)-, -N((C C6)-alkyl-phenyl)- , -N(CO-(CH2)i.10-COOH)- or -NH-; and its pharmaceutically acceptable salts.
2. A compound of the formula I as claimed in claim 1 , wherein R2, R4, R5, R6 independently of one another are H, F, CI, Br, I, CF3, N02l N3, CN, COOH, COO(CrC6)-alkyl, CONH2) CONH(CrC6)-alkyl, CON[(CrC6)-alkyl]2, (C C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, 0- (CrC6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; 165790/2 38 C(=NH)(NH2), PO3H2, S03H, SO2-NH2, S02NH(CrC6)-alkyl, S02N[(d- C6)-alkyl]2 , S-(C C6)-alkyl, S-(CH2)n-phenyl, SO-(CrC6)-alkyl, SO- (CH2)n-phenyl, S02-(Ci-C6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3) N02) CN, OCF3, 0-(C C6)-alkyl, (C C6)-alkyl, NH2; NH2l NH-(C C6)-alkyl, N((C C6)-alkyl)2l NH(C C7)-acyl, phenyl, O- (CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be mono- to trisubstituted by F, CI, Br, I, OH, CF3, N02, CN, OCF3, 0-(C C6)-alkyl, (Ci-C6)-alkyl, NH2, NH(C C6)-alkyl, N((Ci-C6)-alkyl)2, S02-CH3, COOH, COO-(Ci-C6)-alkyl, CONH2; R1 , R3 independently of one another are (C0-C3o)-alkylene-(LAG) and where one or more carbon atoms of the alkylene radical may be replaced by -0-, -(C=0)-, -N(CH3)- or -NH-, H, F, CI, Br, I, CF3, N02, N3, CN, COOH, COO(CrC6)-alkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C C6)-alkyl]2, (C C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, 0-(CrC6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; PO3H2, SO3H, SO2-NH2, S02NH(CrC6)-alkyl, S02N[(C C6)-alkyl]2 , S-(C C6)-alkyl, S-(CH2)n-phenyl, SO-(C Ce)-alkyl, SO- (CH2)n-phenyl, S02-(C CB)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3, N02, CN, OCF3, 0-(C C6)-alkyl, (d-CeJ-alkyl, NH2; NH2, NH-(C C6)-alkyl, N((C C6)-alkyl)2, NH(C C7)-acyl, phenyl, O- (CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be mono- to trisubstituted by F, CI, Br, I, OH, CF3) N02, CN, OCF3, 0-(CrC6)-alkyl, (d-Ce^alkyl, NH2, NH(C C6)-alkyl, N((C C6)-alkyl}2, S02-CH3, COOH, COO-(CrC6)-alkyl, CONH2; (LAG) is a mono-, di- or tricyclic trialkylammonium radical, a mono-, di- or tricyclic trialkylammoniumalkyl radical, -(CH2)o-io-C(=NH)(NH2), -(CH2)o- 10-C(=NH)(NHOH) or -NR7-C(=NR8)(NR9R10); R7, R8, R9 and R10 independently of one another are H, (CrC6)-alkyl, (CrC6)- alkyl-phenyl, phenyl, (C3-C8)-cycloalkyl); where in each case at least one of the radicals R1 or R3 must have the meaning (Co-C3o)-alkylene-(LAG), where one or more carbon atoms of the alkylene radical may be replaced by -0-, -(C=0)-, -N(CH3)- or -NH-; and its physiologically acceptable salts.
3. A compound of the formula I as claimed in claim 1 or 2, wherein R2, R4, R5, R6 independently of one another are H, F, CI, Br, I, CF3, N02> N3l CN, COOH, C00(C C6)-alkyl, CONH2> CONH(Ci-C6)-alkyl, CON[(CrC6)-alkyl]2, (C C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O- (Ci-C6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; C(=NH)(NH2), P03H2, S03H, S02-NH2, S02NH(CrC6)-alkyl, S02N[(C C6)-alkyl]2 , S-(CrC6)-alkyl, S-(CH2)n-phenyl, SO-(C C6)-alkyl, SO- (CH2)n-phenyl, S02-(C C6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3, NO2, CN, OCF3, O-(C.,-C6)-alkyl, (Ci-C6)-alkyl, NH2; NH2, NH-(C C6)-alkyl, N((CrC6)-alkyl)2) NH(C C7)-acyl, phenyl, O- (CH2)n-phenyl, where n = 0 - 6, where the phenyl ring may be mono- to trisubstituted by F, CI, Br, I, OH, CF3, NO2) CN, OCF3, O-(C C6)-alkyl, (C C6)-alkyl, NH2, NH(CrC6)-alkyl, N((CrC6)-alkyl)2, SO2-CH3, COOH, COO-(CrC6)-alkyl, CONH2; 165790/2 40 R1 , R3 independently of one another are -(CH2)o-i-Y-W-(Co-C25)-alkylene-Y'- W'-(LAG), where one or more carbon atoms of the alkylene radical may be replaced by -0-; H, F, CI, Br, I, CF3, N02, N3l CN, COOH, COO(Ci-C6)-alkyl, CONH2, CONH(CrC6)-alkyl, CON[(C C6)-alkyl]2, (CrC6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, 0-(CrC6)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; P03H2, SO3H, S02-NH2, S02NH(Ci-C6)-alkyl, S02N[(C C6)-alkyl]2 , S-(CrC6)-alkyl, S-(CH2)n-phenyl, SO-(CrC6)-alkyl, SO- (CH2)n-phenyl, S02-(Ci-C6)-alkyl, S02-(CH2)n-phenyl, where n = 0 - 6 . and the phenyl radical may be substituted up to two times by F, CI, Br, OH, CF3, N02, CN, OCF3, O-id-CeJ-alkyl, (C C6)-alkyl, NH2; NH2, NH-(CrC6)-alkyl, N((CrC6}-alkyl)2, NH(CrC7)-acyl, phenyl, O- (CH2)n-phenyl, where n = 0 - 6, the phenyl ring may be mono- to trisubstituted by F, CI, Br, I, OH, CF3) N02, CN, OCF3, 0-(C C6)-alkyl, (Ci-C6)-alkyl, NH2, NH(C C6)-alkyl, N((Ci-C6)-alkyl)2, S02-CH3) COOH, COO-id-CeJ-alkyl, CONH2; Y, W, Y* W independently of one another are NH, NCH3, C=0, O, a bond or S(0)„, where n=0-2; or Y-W or Y'-W taken together are each a bond. (LAG) is a mono-, di- or tricyclic trialkylammonium radical, a mono-, di- or tricyclic trialkylammoniumalkyl radical, -(CH2)o- 10-C(=NH)(NHOH) or -NR7-C(=NR8)(NR9R10); R7, R8, R9 and R10 independently of one another are H, (CrC6)-alkyl, (CrC6)-alkyl- phenyl, phenyl, (C3-C8)-cycloalkyl); 165790/2 41 where in each case at least one of the radicals R1 or R3 must have the meaning -(CH2)o-rY-W-(Co-C25)-alkylene-Y'-W'-(LAG), where one or more carbon atoms of the alkylene radical may be replaced by -0-; and its pharmaceutically acceptable salts.
4. A compound of the formula I as claimed in one or more of claims 1 to 3, wherein LAG is a tricyclic trialkylammoniumalkyl radical, and its pharmaceutically acceptable salts.
5. A medicament comprising an effective amount of one or more compounds as claimed in one or more of claims 1 to 4.
6. A medicament comprising one or more compounds as claimed in one or more of claims 1 to 4 and at least one further active compound.
7. The medicament as claimed in claim 6, comprising, as further active compound, one or more compounds which normalize lipid metabolism.
8. The medicament as claimed in claim 6 or 7, which comprises, as further active compound, one or more antidiabetics, hypoglycemically active compounds, HMGCoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbers, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, a-glucosidase inhibitors, active compounds which act on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin-reuptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, decoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-p-agonists or amphetamines.
9. A compound as claimed in one or more of claims 1 to 4 for use as a medicament for the treatment of impaired lipid metabolism.
10. A process for preparing a medicament comprising one or more of the compounds as claimed in one or more of claims 1 to 4, which comprises mixing the. active compound with a pharmaceutically acceptable carrier and bringing this mixture into a form suitable for administration.
11. The use of the compounds as claimed in one or more of claims 1 to 4 for preparing a medicament for treating hyperlipidemia.
12. The use of the compounds as claimed in one or more of claims 1 to 4 for preparing a medicament for lowering the serum cholesterol concentration.
13. The use of the compounds as claimed in one or more of claims 1 to 4 for preparing a medicament for treating arteriosclerotic manifestations.
14. The use of the compounds as claimed in one or more of claims 1 to 4 for preparing a medicament for treating insulin resistance.
15. The compound according to any one of claims 1-4,9 substantially as described hereinabove.
16. The medicament according to any one of claims 5-8 substantially as described hereinabove.
17. The process according to claim 10 substantially as described hereinabove.
18. The use according to any one of claims 11-14 substantially as described hereinabove. P- 7420-IL
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10227507A DE10227507A1 (en) | 2002-06-19 | 2002-06-19 | Cationically substituted diphenylazetidinones, processes for their preparation, medicaments containing these compounds and their use |
PCT/EP2003/005814 WO2004000803A1 (en) | 2002-06-19 | 2003-06-04 | Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
IL165790A0 IL165790A0 (en) | 2006-01-15 |
IL165790A true IL165790A (en) | 2010-04-15 |
Family
ID=29719282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL165790A IL165790A (en) | 2002-06-19 | 2004-12-15 | Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1517890B1 (en) |
JP (1) | JP2005533071A (en) |
KR (1) | KR20050010061A (en) |
CN (1) | CN1662494A (en) |
AT (1) | ATE401304T1 (en) |
AU (1) | AU2003238209B2 (en) |
BR (1) | BR0311984A (en) |
CA (1) | CA2490108A1 (en) |
DE (2) | DE10227507A1 (en) |
DK (1) | DK1517890T3 (en) |
ES (1) | ES2310662T3 (en) |
HR (1) | HRP20041202A2 (en) |
IL (1) | IL165790A (en) |
MA (1) | MA27251A1 (en) |
MX (1) | MXPA04012308A (en) |
NO (1) | NO20050088L (en) |
PA (1) | PA8575601A1 (en) |
PL (1) | PL372660A1 (en) |
PT (1) | PT1517890E (en) |
RS (1) | RS108604A (en) |
RU (1) | RU2315753C2 (en) |
SV (1) | SV2004001555A (en) |
TW (1) | TW200406380A (en) |
UY (1) | UY27852A1 (en) |
WO (1) | WO2004000803A1 (en) |
ZA (1) | ZA200409379B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
CA2550215A1 (en) | 2003-12-23 | 2005-07-07 | Astrazeneca Ab | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
MX2007006695A (en) | 2004-12-03 | 2007-08-14 | Schering Corp | Substituted piperazines as cb1 antagonists. |
WO2006107936A1 (en) * | 2005-04-04 | 2006-10-12 | Pontificia Universidad Catolica De Chile | The use of ezetimibe in the prevention and treatment of cholesterol gallstones |
WO2007001975A1 (en) | 2005-06-20 | 2007-01-04 | Schering Corporation | Piperidine derivatives useful as histamine h3 antagonists |
SA06270191B1 (en) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions |
TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
BRPI0715160A2 (en) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | arylamimoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, drugs comprising these compounds, and their use |
DE102007002260A1 (en) | 2007-01-16 | 2008-07-31 | Sanofi-Aventis | Use of substituted pyranonic acid derivatives for the preparation of medicaments for the treatment of the metabolic syndrome |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
DE102007054497B3 (en) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy-hexyl)-amide useful e.g. to treat hyperlipidemia |
EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
CA2754384A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
CN101993403B (en) | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | Azetidinone compound and medical applications thereof |
SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2582709B1 (en) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2766349B1 (en) | 2011-03-08 | 2016-06-01 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683700B1 (en) | 2011-03-08 | 2015-02-18 | Sanofi | Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10042447A1 (en) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Vertebrate intestinal protein that absorbs cholesterol and use of this protein to identify inhibitors of intestinal cholesterol transport |
CA2431995A1 (en) * | 2000-12-21 | 2002-06-27 | Aventis Pharma Deutschland Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
RS50864B (en) * | 2000-12-21 | 2010-08-31 | Sanofi-Aventis Deutschland Gmbh. | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
-
2002
- 2002-06-19 DE DE10227507A patent/DE10227507A1/en not_active Withdrawn
-
2003
- 2003-06-04 RU RU2005101088/04A patent/RU2315753C2/en not_active IP Right Cessation
- 2003-06-04 PL PL03372660A patent/PL372660A1/en not_active Application Discontinuation
- 2003-06-04 EP EP03735534A patent/EP1517890B1/en not_active Expired - Lifetime
- 2003-06-04 JP JP2004514659A patent/JP2005533071A/en not_active Abandoned
- 2003-06-04 PT PT03735534T patent/PT1517890E/en unknown
- 2003-06-04 DK DK03735534T patent/DK1517890T3/en active
- 2003-06-04 ES ES03735534T patent/ES2310662T3/en not_active Expired - Lifetime
- 2003-06-04 RS YUP-1086/04A patent/RS108604A/en unknown
- 2003-06-04 BR BR0311984-0A patent/BR0311984A/en not_active IP Right Cessation
- 2003-06-04 AU AU2003238209A patent/AU2003238209B2/en not_active Ceased
- 2003-06-04 DE DE50310161T patent/DE50310161D1/en not_active Expired - Lifetime
- 2003-06-04 WO PCT/EP2003/005814 patent/WO2004000803A1/en active IP Right Grant
- 2003-06-04 KR KR10-2004-7020518A patent/KR20050010061A/en not_active Application Discontinuation
- 2003-06-04 CA CA002490108A patent/CA2490108A1/en not_active Abandoned
- 2003-06-04 CN CN038140934A patent/CN1662494A/en active Pending
- 2003-06-04 MX MXPA04012308A patent/MXPA04012308A/en active IP Right Grant
- 2003-06-04 AT AT03735534T patent/ATE401304T1/en not_active IP Right Cessation
- 2003-06-13 PA PA20038575601A patent/PA8575601A1/en unknown
- 2003-06-16 SV SV2003001555A patent/SV2004001555A/en unknown
- 2003-06-16 UY UY27852A patent/UY27852A1/en unknown
- 2003-06-17 TW TW092116320A patent/TW200406380A/en unknown
-
2004
- 2004-11-22 ZA ZA200409379A patent/ZA200409379B/en unknown
- 2004-12-08 MA MA27989A patent/MA27251A1/en unknown
- 2004-12-15 IL IL165790A patent/IL165790A/en not_active IP Right Cessation
- 2004-12-17 HR HR20041202A patent/HRP20041202A2/en not_active Application Discontinuation
-
2005
- 2005-01-06 NO NO20050088A patent/NO20050088L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2490108A1 (en) | 2003-12-31 |
KR20050010061A (en) | 2005-01-26 |
ES2310662T3 (en) | 2009-01-16 |
EP1517890B1 (en) | 2008-07-16 |
PA8575601A1 (en) | 2004-02-07 |
ATE401304T1 (en) | 2008-08-15 |
DE50310161D1 (en) | 2008-08-28 |
UY27852A1 (en) | 2003-12-31 |
BR0311984A (en) | 2005-04-26 |
RU2005101088A (en) | 2005-06-27 |
TW200406380A (en) | 2004-05-01 |
DE10227507A1 (en) | 2004-01-08 |
ZA200409379B (en) | 2006-05-31 |
PL372660A1 (en) | 2005-07-25 |
NO20050088L (en) | 2005-01-06 |
RU2315753C2 (en) | 2008-01-27 |
IL165790A0 (en) | 2006-01-15 |
PT1517890E (en) | 2008-10-14 |
AU2003238209A1 (en) | 2004-01-06 |
HRP20041202A2 (en) | 2005-06-30 |
EP1517890A1 (en) | 2005-03-30 |
RS108604A (en) | 2007-02-05 |
DK1517890T3 (en) | 2008-11-10 |
MA27251A1 (en) | 2005-03-01 |
WO2004000803A1 (en) | 2003-12-31 |
AU2003238209B2 (en) | 2009-01-22 |
CN1662494A (en) | 2005-08-31 |
SV2004001555A (en) | 2004-03-19 |
MXPA04012308A (en) | 2005-02-25 |
JP2005533071A (en) | 2005-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL165790A (en) | Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof | |
CA2431983A1 (en) | Novel 1,2-diphenylazetidinones, processes for their preparation, medicaments comprising these compounds and their use for treating impaired lipid metabolism | |
JP2004516293A5 (en) | ||
JP2005533071A5 (en) | ||
RU2005101093A (en) | SUBSTITUTED BY ACID GROUPS OF DIPHENYLAZETIDINONES, METHOD FOR PRODUCING THERE CONTAINING THESE COMPOUNDS OF MEDICINES, AND THEIR APPLICATION | |
RU2005101091A (en) | SUBSTITUTED DIPHENYLAZETIDINONES IN CYCLES, METHOD FOR PRODUCING THESE, CONTAINING THESE COMPOUNDS, MEDICINES AND THEIR APPLICATION | |
JP2012513390A5 (en) | ||
DE602005013248D1 (en) | AMID DERIVATIVES OF 3-PHENYLDIHYDROPYRIMIDOÄ4,5-DÜPYRIMIDINONES, THEIR PREPARATION AND USE AS PHARMACEUTICAL AGENTS | |
BR9510168A (en) | Polyamino acid compound composition unit dosage form and method for preparing a composition | |
RU2009103810A (en) | NEW COMPOUNDS | |
NZ526594A (en) | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use | |
BR0313160A (en) | Compound, pharmaceutical composition, methods for treating a condition and a susceptible neoplasm in an animal in an animal, process for preparing a compound and use of a compound. | |
BR0212277A (en) | Compound, process for preparing a compound, use of a compound, method for producing an ibat inhibitory effect, and pharmaceutical composition | |
NZ515282A (en) | Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions | |
PE20040999A1 (en) | NEW PYRAZOLOPYRIMIDINES AS INHIBITORS OF CYCLINE-DEPENDENT KINASES | |
RU2008108618A (en) | 3, 5-DISPLACED PHENYL-PIPERIDINES AS DOPAMINE NEURO TRANSMISSION MODULATORS | |
FI942910A0 (en) | New phosphonic succinic acid derivatives, process for their preparation and drugs containing these compounds | |
KR960030940A (en) | Improved platinum complexes | |
JP2008524127A5 (en) | ||
IN2015DN00818A (en) | ||
JP2005505538A5 (en) | ||
ATE361749T1 (en) | BENZTHIAZOLE-3 OXIDES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | |
DE602005008633D1 (en) | IMIDAZOÄ1,5AÜTRIAZOLOÄ1,5DÜBENZODIAZEPINE DERIVATIVE FOR THE TREATMENT OF COGNITIVE DISORDER | |
JP2006517933A5 (en) | ||
RU2006131307A (en) | Cycloalkyl-substituted derivatives of 7-amino-4-quinolone-3-carboxylic acid, a method for their preparation and their use as drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
MM9K | Patent not in force due to non-payment of renewal fees |